PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

New Developments in Breast Cancer and Their Impact on Daily Practice in Pathology.

Abstract Advances in research have transformed our understanding of breast cancers and have altered the daily practice of pathology. Theranostic evaluations performed by pathologists are now critical in triaging the patients into appropriate treatment groups, as are new guidelines that were recently established for the evaluation of HER2/neu gene amplification. Emerging molecular classifications of breast cancers bring novel perspectives to the assessment of individual cases, and opportunities for better treatments. Molecular studies have particularly shed light on distinct biological subsets of triple-negative breast cancers, for which new targeted therapies are being developed. The prognostic and therapeutic utility of new histopathologic parameters, such as tumor-infiltrating lymphocytes, are also being elucidated, and new protocols have been devised for the pathologic evaluation of breast specimens that have undergone neoadjuvant treatment. Novel clinical practices, such as radioactive seed localization, also affect the way breast specimens are processed and evaluated. In this brief review, we highlight the developments that are most relevant to pathology and are changing or could potentially impact our daily practice.
PMID
Related Publications

Clinical implications of the intrinsic molecular subtypes of breast cancer.

WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial.

The Impact of New Technologic and Molecular Advances in the Daily Practice of Gastrointestinal and Hepatobiliary Pathology.

Breast pathology 2014.

PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.

Authors

Mayor MeshTerms
Keywords
Journal Title archives of pathology & laboratory medicine
Publication Year Start




PMID- 28353377
OWN - NLM
STAT- MEDLINE
DA  - 20170329
DCOM- 20170418
LR  - 20170418
IS  - 1543-2165 (Electronic)
IS  - 0003-9985 (Linking)
VI  - 141
IP  - 4
DP  - 2017 Apr
TI  - New Developments in Breast Cancer and Their Impact on Daily Practice in
      Pathology.
PG  - 490-498
LID - 10.5858/arpa.2016-0288-SA [doi]
AB  - Advances in research have transformed our understanding of breast cancers and
      have altered the daily practice of pathology. Theranostic evaluations performed
      by pathologists are now critical in triaging the patients into appropriate
      treatment groups, as are new guidelines that were recently established for the
      evaluation of HER2/neu gene amplification. Emerging molecular classifications of 
      breast cancers bring novel perspectives to the assessment of individual cases,
      and opportunities for better treatments. Molecular studies have particularly shed
      light on distinct biological subsets of triple-negative breast cancers, for which
      new targeted therapies are being developed. The prognostic and therapeutic
      utility of new histopathologic parameters, such as tumor-infiltrating
      lymphocytes, are also being elucidated, and new protocols have been devised for
      the pathologic evaluation of breast specimens that have undergone neoadjuvant
      treatment. Novel clinical practices, such as radioactive seed localization, also 
      affect the way breast specimens are processed and evaluated. In this brief
      review, we highlight the developments that are most relevant to pathology and are
      changing or could potentially impact our daily practice.
FAU - Li, Xiaoxian
AU  - Li X
FAU - Oprea-Ilies, Gabriela M
AU  - Oprea-Ilies GM
FAU - Krishnamurti, Uma
AU  - Krishnamurti U
AD  - From the Department of Pathology and Laboratory Medicine, Emory University,
      Atlanta, Gerogia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170228
PL  - United States
TA  - Arch Pathol Lab Med
JT  - Archives of pathology & laboratory medicine
JID - 7607091
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - AIM
SB  - IM
MH  - Breast Neoplasms/classification/*genetics/*therapy
MH  - Female
MH  - Gene Amplification
MH  - Humans
MH  - Molecular Targeted Therapy/*methods/trends
MH  - Neoadjuvant Therapy/methods/trends
MH  - Pathology, Clinical/*methods/trends
MH  - Receptor, ErbB-2/genetics
MH  - Signal Transduction/drug effects/genetics
MH  - Triple Negative Breast Neoplasms/genetics/therapy
EDAT- 2017/03/30 06:00
MHDA- 2017/04/19 06:00
CRDT- 2017/03/30 06:00
AID - 10.5858/arpa.2016-0288-SA [doi]
PST - ppublish
SO  - Arch Pathol Lab Med. 2017 Apr;141(4):490-498. doi: 10.5858/arpa.2016-0288-SA.
      Epub 2017 Feb 28.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>